Genasys Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Genasys Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Sep 30, 2018 | $26.31M | Dec 21, 2018 |
| FY2018 | Sep 30, 2017 | $20.31M | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | $16.36M | Dec 13, 2017 |
| FY2016 | Sep 30, 2015 | $16.78M | Dec 7, 2016 |
| FY2015 | Sep 30, 2014 | $24.59M | Dec 3, 2015 |
| FY2014 | Sep 30, 2013 | $17.09M | Nov 20, 2014 |
| FY2013 | Sep 30, 2012 | $14.79M | Nov 21, 2013 |
| FY2012 | Sep 30, 2011 | $26.51M | Dec 4, 2012 |
| FY2011 | Sep 30, 2010 | $16.69M | Dec 5, 2011 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $16.96M | Dec 15, 2025 |
| FY2025 | Sep 30, 2024 | $10.19M | Dec 15, 2025 |
| FY2024 | Sep 30, 2023 | $21.76M | Dec 13, 2024 |
| FY2023 | Sep 30, 2022 | $27.28M | Dec 7, 2023 |
| FY2022 | Sep 30, 2021 | $23.43M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $22.64M | Nov 23, 2021 |
| FY2020 | Sep 30, 2019 | $18.46M | Dec 10, 2020 |
| FY2019 | Sep 30, 2018 | $12.74M | Dec 10, 2019 |
| FY2018 | Sep 30, 2017 | $10.28M | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | $7.67M | Dec 13, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($18.11M) | Dec 15, 2025 |
| FY2025 | Sep 30, 2024 | ($31.73M) | Dec 15, 2025 |
| FY2024 | Sep 30, 2023 | ($18.40M) | Dec 13, 2024 |
| FY2023 | Sep 30, 2022 | ($16.21M) | Dec 7, 2023 |
| FY2022 | Sep 30, 2021 | $704.0K | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $11.87M | Nov 23, 2021 |
| FY2020 | Sep 30, 2019 | $2.79M | Dec 10, 2020 |
| FY2019 | Sep 30, 2018 | ($3.75M) | Dec 10, 2019 |
| FY2018 | Sep 30, 2017 | ($876.8K) | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | ($1.28M) | Dec 13, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($16.81M) | Dec 15, 2025 |
| FY2025 | Sep 30, 2024 | ($26.72M) | Dec 15, 2025 |
| FY2024 | Sep 30, 2023 | ($10.99M) | Dec 13, 2024 |
| FY2023 | Sep 30, 2022 | ($15.53M) | Dec 7, 2023 |
| FY2022 | Sep 30, 2021 | $1.08M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $6.04M | Nov 23, 2021 |
| FY2020 | Sep 30, 2019 | $3.14M | Dec 10, 2020 |
| FY2019 | Sep 30, 2018 | ($1.48M) | Dec 10, 2019 |
| FY2018 | Sep 30, 2017 | ($807.7K) | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | ($1.59M) | Dec 13, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $8.11M | Dec 15, 2025 |
| FY2025 | Sep 30, 2024 | $9.64M | Dec 15, 2025 |
| FY2024 | Sep 30, 2023 | $8.13M | Dec 13, 2024 |
| FY2023 | Sep 30, 2022 | $7.01M | Dec 7, 2023 |
| FY2022 | Sep 30, 2021 | $4.92M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $4.55M | Nov 23, 2021 |
| FY2020 | Sep 30, 2019 | $4.53M | Dec 10, 2020 |
| FY2019 | Sep 30, 2018 | $3.52M | Dec 10, 2019 |
| FY2018 | Sep 30, 2017 | $2.50M | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | $2.39M | Dec 13, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $25.66M | Dec 15, 2025 |
| FY2025 | Sep 30, 2024 | $27.26M | Dec 15, 2025 |
| FY2024 | Sep 30, 2023 | $24.62M | Dec 13, 2024 |
| FY2023 | Sep 30, 2022 | $22.64M | Dec 7, 2023 |
| FY2022 | Sep 30, 2021 | $17.42M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $12.04M | Nov 23, 2021 |
| FY2020 | Sep 30, 2019 | $10.79M | Dec 10, 2020 |
| FY2019 | Sep 30, 2018 | $10.69M | Dec 10, 2019 |
| FY2018 | Sep 30, 2017 | $8.59M | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | $6.88M | Dec 13, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($8.76M) | Dec 15, 2025 |
| FY2025 | Sep 30, 2024 | ($19.45M) | Dec 15, 2025 |
| FY2024 | Sep 30, 2023 | ($9.59M) | Dec 13, 2024 |
| FY2023 | Sep 30, 2022 | $468.0K | Dec 7, 2023 |
| FY2022 | Sep 30, 2021 | $6.15M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $6.92M | Nov 23, 2021 |
| FY2020 | Sep 30, 2019 | $9.86M | Dec 10, 2020 |
| FY2019 | Sep 30, 2018 | $1.25M | Dec 10, 2019 |
| FY2018 | Sep 30, 2017 | ($666.8K) | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | ($1.15M) | Dec 13, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $255.0K | Dec 15, 2025 |
| FY2025 | Sep 30, 2024 | $191.0K | Dec 15, 2025 |
| FY2024 | Sep 30, 2023 | $239.0K | Dec 13, 2024 |
| FY2023 | Sep 30, 2022 | $381.0K | Dec 7, 2023 |
| FY2022 | Sep 30, 2021 | $208.0K | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $140.0K | Nov 23, 2021 |
| FY2020 | Sep 30, 2019 | $343.0K | Dec 10, 2020 |
| FY2019 | Sep 30, 2018 | $625.8K | Dec 10, 2019 |
| FY2018 | Sep 30, 2017 | $182.3K | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | $162.3K | Dec 13, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $63.87M | Dec 15, 2025 |
| FY2025 | Sep 30, 2024 | $53.94M | Dec 15, 2025 |
| FY2024 | Sep 30, 2023 | $49.91M | Dec 13, 2024 |
| FY2023 | Sep 30, 2022 | $71.85M | Dec 7, 2023 |
| FY2022 | Sep 30, 2021 | $90.13M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $66.17M | Nov 23, 2021 |
| FY2020 | Sep 30, 2019 | $47.12M | Dec 10, 2020 |
| FY2019 | Sep 30, 2018 | $41.86M | Dec 10, 2019 |
| FY2018 | Sep 30, 2017 | $38.86M | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | $36.81M | Dec 13, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $61.70M | Dec 15, 2025 |
| FY2025 | Sep 30, 2024 | $36.37M | Dec 15, 2025 |
| FY2024 | Sep 30, 2023 | $16.09M | Dec 13, 2024 |
| FY2023 | Sep 30, 2022 | $21.46M | Dec 7, 2023 |
| FY2022 | Sep 30, 2021 | $24.17M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $17.03M | Nov 23, 2021 |
| FY2020 | Sep 30, 2019 | $11.74M | Dec 10, 2020 |
| FY2019 | Sep 30, 2018 | $8.37M | Dec 10, 2019 |
| FY2018 | Sep 30, 2017 | $3.67M | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | $2.24M | Dec 13, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $2.17M | Dec 15, 2025 |
| FY2025 | Sep 30, 2024 | $17.56M | Dec 15, 2025 |
| FY2025 | Sep 30, 2023 | $33.81M | Dec 15, 2025 |
| FY2024 | Sep 30, 2022 | $50.39M | Dec 13, 2024 |
| FY2023 | Sep 30, 2021 | $65.96M | Dec 7, 2023 |
| FY2022 | Sep 30, 2020 | $49.14M | Dec 16, 2022 |
| FY2021 | Sep 30, 2019 | $35.38M | Nov 23, 2021 |
| FY2020 | Sep 30, 2018 | $33.49M | Dec 10, 2020 |
| FY2019 | Sep 30, 2017 | $35.18M | Dec 10, 2019 |
| FY2018 | Sep 30, 2016 | $34.57M | Dec 21, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $13.45M | Dec 15, 2025 |
| FY2025 | Sep 30, 2024 | $13.33M | Dec 15, 2025 |
| FY2025 | Sep 30, 2023 | $10.28M | Dec 15, 2025 |
| FY2023 | Sep 30, 2022 | $10.12M | Dec 7, 2023 |
| FY2022 | Sep 30, 2021 | $23.83M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $2.47M | Nov 23, 2021 |
| FY2020 | Sep 30, 2019 | $2.31M | Dec 10, 2020 |
| FY2019 | Sep 30, 2018 | $2.45M | Dec 10, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($125.90M) | Dec 15, 2025 |
| FY2025 | Sep 30, 2024 | ($107.79M) | Dec 15, 2025 |
| FY2024 | Sep 30, 2023 | ($76.06M) | Dec 13, 2024 |
| FY2023 | Sep 30, 2022 | ($57.37M) | Dec 7, 2023 |
| FY2022 | Sep 30, 2021 | ($41.15M) | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | ($41.86M) | Nov 23, 2021 |
| FY2020 | Sep 30, 2019 | ($53.73M) | Dec 10, 2020 |
| FY2019 | Sep 30, 2018 | ($56.52M) | Dec 10, 2019 |
| FY2018 | Sep 30, 2017 | ($52.77M) | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | ($51.90M) | Dec 13, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $7.97M | Dec 15, 2025 |
| FY2025 | Sep 30, 2024 | $4.95M | Dec 15, 2025 |
| FY2024 | Sep 30, 2023 | $8.67M | Dec 13, 2024 |
| FY2023 | Sep 30, 2022 | $12.74M | Dec 7, 2023 |
| FY2022 | Sep 30, 2021 | $13.17M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $23.32M | Nov 23, 2021 |
| FY2020 | Sep 30, 2019 | $18.82M | Dec 10, 2020 |
| FY2019 | Sep 30, 2018 | $11.06M | Dec 10, 2019 |
| FY2018 | Sep 30, 2017 | $12.76M | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | $13.47M | Dec 13, 2017 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Sep 30, 2022 | $0 | Dec 16, 2022 |
| FY2022 | Sep 30, 2021 | $296.0K | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $318.0K | Nov 23, 2021 |
| FY2019 | Sep 30, 2019 | $312.5K | Dec 10, 2019 |
| FY2018 | Sep 30, 2018 | $349.0K | Dec 21, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Dec 15, 2025 |
| FY2025 | Sep 30, 2024 | 0 | Dec 15, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Dec 13, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Dec 7, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Nov 23, 2021 |
| FY2020 | Sep 30, 2019 | 0 | Dec 10, 2020 |
| FY2019 | Sep 30, 2018 | 0 | Dec 10, 2019 |
| FY2018 | Sep 30, 2017 | 0 | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | 0 | Dec 13, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Dec 15, 2025 |
| FY2025 | Sep 30, 2024 | 0 | Dec 15, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Dec 13, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Dec 7, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Nov 23, 2021 |
| FY2020 | Sep 30, 2019 | 0 | Dec 10, 2020 |
| FY2019 | Sep 30, 2018 | 0 | Dec 10, 2019 |
| FY2018 | Sep 30, 2017 | 0 | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | 0 | Dec 13, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 45.16M | Dec 15, 2025 |
| FY2025 | Sep 30, 2024 | 44.63M | Dec 15, 2025 |
| FY2024 | Sep 30, 2023 | 36.61M | Dec 13, 2024 |
| FY2023 | Sep 30, 2022 | 36.61M | Dec 7, 2023 |
| FY2022 | Sep 30, 2021 | 36.40M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | 33.56M | Nov 23, 2021 |
| FY2020 | Sep 30, 2019 | 32.95M | Dec 10, 2020 |
| FY2019 | Sep 30, 2018 | 33.18M | Dec 10, 2019 |
| FY2018 | Sep 30, 2017 | 32.16M | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | 31.80M | Dec 13, 2017 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Sep 30, 2019 | $0 | Dec 10, 2019 |
| FY2019 | Sep 30, 2018 | $0 | Dec 10, 2019 |
| FY2018 | Sep 30, 2017 | $0 | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | $954.7K | Dec 13, 2017 |